Form 8-K - Current report:
SEC Accession No. 0000950170-23-032300
Filing Date
2023-07-10
Accepted
2023-07-07 19:10:02
Documents
13
Period of Report
2023-07-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kalv-20230707.htm   iXBRL 8-K 57822
2 EX-99.1 kalv-ex99_1.htm EX-99.1 248563
  Complete submission text file 0000950170-23-032300.txt   436840

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kalv-20230707.xsd EX-101.SCH 2469
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kalv-20230707_pre.xml EX-101.PRE 9843
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kalv-20230707_lab.xml EX-101.LAB 13360
7 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20230707_htm.xml XML 4718
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 231077973
SIC: 2834 Pharmaceutical Preparations